HCW Biologics annual stock-based compensation
2020
2021
2022
2023
2024
2025
HCW Biologics Stock-Based Compensation Growth & History (HCWB)
HCW Biologics's stock-based compensation was $768,623 for fiscal 2025.
View full HCW Biologics company overviewHCW Biologics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $768,623 | −$240,388 | −23.82% |
| 2024 | 2024-12-31 | $1.0M | $5,262 | +0.52% |
| 2023 | 2023-12-31 | $1.0M | −$116,442 | −10.39% |
| 2022 | 2022-12-31 | $1.1M | $759,216 | +210.32% |
| 2021 | 2021-12-31 | $360,975 | $339,100 | +1550.17% |
| 2020 | 2020-12-31 | $21,875 | — | — |
HCW Biologics quarterly stock-based compensation
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1,220 | −$277,087 | −99.56% |
| Q1 2026 | 2026-03-31 | $10,019 | −$265,623 | −96.37% |
| Q4 2025 | 2025-12-31 | $9,182 | −$282,889 | −96.86% |
| Q3 2025 | 2025-09-30 | $205,492 | −$26,942 | −11.59% |
| Q2 2025 | 2025-06-30 | $278,307 | $38,486 | +16.05% |
| Q1 2025 | 2025-03-31 | $275,642 | $30,957 | +12.65% |
| Q4 2024 | 2024-12-31 | $292,071 | $30,799 | +11.79% |
| Q3 2024 | 2024-09-30 | $232,434 | $12,586 | +5.72% |
| Q2 2024 | 2024-06-30 | $239,821 | −$23,602 | −8.96% |
| Q1 2024 | 2024-03-31 | $244,685 | −$14,521 | −5.60% |
| Q4 2023 | 2023-12-31 | $261,272 | −$24,916 | −8.71% |
| Q3 2023 | 2023-09-30 | $219,848 | −$82,472 | −27.28% |
| Q2 2023 | 2023-06-30 | $263,423 | −$7,912 | −2.92% |
| Q1 2023 | 2023-03-31 | $259,206 | −$1,142 | −0.44% |
| Q4 2022 | 2022-12-31 | $286,188 | — | — |
| Q3 2022 | 2022-09-30 | $302,320 | $300,660 | +18112.05% |
| Q2 2022 | 2022-06-30 | $271,335 | — | — |
| Q1 2022 | 2022-03-31 | $260,348 | — | — |
| Q3 2021 | 2021-09-30 | $1,660 | — | — |
HCW Biologics stock-based compensation trends
Over the last five fiscal years, HCW Biologics's stock-based compensation increased from $21,875 to $768,623, a change of $746,748. The latest reported quarter, Q2 2026, shows $1,220.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review HCW Biologics source filings ↗